3-[2-(3-carboxyprop-2-enoylamino)ethylcarbamoyl]prop-2-enoic acid
|
- $62 - $142
- Product name: 3-[2-(3-carboxyprop-2-enoylamino)ethylcarbamoyl]prop-2-enoic acid
- CAS: 7126-27-4
- MF: C10H12N2O6
- MW: 256.21
- EINECS:
- MDL Number:MFCD32263476
- Synonyms:3-[2-(3-carboxyprop-2-enoylamino)ethylcarbamoyl]prop-2-enoic acid;4-[2-(3-carboxyprop-2-enoylamino)ethylamino]-4-oxobut-2-enoic acid;(2E,2E)-4,4-(ethane-1,2-diylbis(azanediyl))bis(4-oxobut-2-enoic acid);N,N'-Ethylenebis(maleamic Acid);(2Z,2'Z)-4,4'-(1,2-Ethanediyldiimino)bis[4-oxo-2-butenoic Acid];2-Butenoic acid, 4,4'-(1,2-ethanediyldiimino)bis[4-oxo-, (2Z,2'Z)-;(2Z,2'Z)-4,4'-(ethane-1,2-diylbis(azanediyl))bis(4-oxobut-2-enoic acid)
2 prices
Selected condition:
Brand
- Aaron Chemicals
- TCI Chemical
Package
- 250mg
- 1G
- ManufacturerAaron Chemicals
- Product numberAR01H9OL
- Product description3-[2-(3-carboxyprop-2-enoylamino)ethylcarbamoyl]prop-2-enoicacid 95%
- Packaging250mg
- Price$62
- Updated2021-12-16
- Buy
- ManufacturerTCI Chemical
- Product numberE1399
- Product descriptionN,N'-Ethylenebis(maleamic Acid)
- Packaging1G
- Price$142
- Updated2025-07-31
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Aaron Chemicals | AR01H9OL | 3-[2-(3-carboxyprop-2-enoylamino)ethylcarbamoyl]prop-2-enoicacid 95% | 250mg | $62 | 2021-12-16 | Buy |
| TCI Chemical | E1399 | N,N'-Ethylenebis(maleamic Acid) | 1G | $142 | 2025-07-31 | Buy |
Properties
Melting point :182 °C
Boiling point :712.1±60.0 °C(Predicted)
Density :1.408±0.06 g/cm3(Predicted)
form :powder to crystal
pka :2.57±0.25(Predicted)
color :White to Light yellow
Boiling point :712.1±60.0 °C(Predicted)
Density :1.408±0.06 g/cm3(Predicted)
form :powder to crystal
pka :2.57±0.25(Predicted)
color :White to Light yellow
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||
| Precautionary statements: |
|




